Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|May 19, 2005
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.Basic & Clinical Pharmacology & Toxicology|July 27, 2006
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitorsTiina Jaakkola, Jouko Laitila, Pertti J Neuvonen, et al.European Journal of Clinical Pharmacology|February 1, 2006
Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinideLauri I Kajosaari, Tiina Jaakkola, Pertti J Neuvonen, et al.European Journal of Clinical Pharmacology|May 4, 2006
Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.British Journal of Clinical Pharmacology|January 5, 2006
Effect of rifampicin on the pharmacokinetics of pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.Biomaterials|April 19, 2002
In vitro evaluation of poly(epsilon-caprolactone-co-DL-lactide)/ bioactive glass compositesJaana Rich, Tiina Jaakkola, Teemu Tirri, et al.Biomaterials|February 21, 2003
Bone response to degradable thermoplastic composite in rabbitsTimo O Närhi, John A Jansen, Tiina Jaakkola, et al.Pageof 1